Comparison of Metformin and Myoinositol In Improving Insulin Sensitivity of Women with Polycystic Ovarian Syndrome

Objective: To determine the outcome of Metformin versus Myoinositol in women with polycystic ovarian syndrome.” Study Design: Quasi-experimental study Place and Duration of Study: Department of Obstetrics & Gynecology, Avicenna Medical Hospital Lahore for 06 months (Oct-2022 to March-2023). Methodology: One hundred patients were enrolled and divided in two Groups. In Group A, females were given Myo-inositol. In Group B, females were given Metformin. After 24 weeks, blood sample was taken for assessment of HOMA-IR. Reports were assessed and HOMA-IR level was recorded. Reduction in HOMA-IR in blood after 24 weeks of treatment was calculated. Information was recorded in proforma and analyzed in SPSS 23. Results: The mean age of females in Myoinositol Group was 29.76±9.11 years while the mean age of females in Metformin Group was 32.52±8.81 years. In Myoinositol Group, 13(26%) had primary infertility and 25(50%) had secondary infertility. In Metformin Group, 7(14%) had primary infertility and 28(56%) had secondary infertility. In Myoinositol Group, the mean HOMA-IR at baseline was recorded as 27.59±19.10 that was reduced to 21.28±15.38. In Metformin Group, the mean HOMA-IR at baseline was recorded as 24.13±12.32 that was changed to 16.55±7.56. The difference in both Groups at baseline was insignificant as well as after 24 weeks, however the HOMA-IR was less in Metformin Group (p-value >0.05). Conclusion: Thus there is no difference in the HOMA-IR level whether Metformin is prescribed or Myoinositol is prescribed